Xenon Q2 net loss $110.7M; NDA for azetukalner on track for Q3 2026

Xenon Pharmaceuticals Inc.

Net loss of $110.7M in Q2 2026 vs $84.7M in Q2 2025; R&D expenses rose to $99.2M.
Cash and securities $1.245B as of June 30, 2026; cash runway into 2029.
NDA submission for azetukalner in FOS remains on track for Q3 2026 after pre-NDA meeting with FDA.
Phase 3 X-NOVA2 topline data in MDD expected H1 2027; X-TOLE3 and X-ACKT enrollment ongoing.
Phase 1 studies for XEN1701, XEN1720 (NaV1.7) and XEN1120 (KV7) expected to complete H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.